STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
STAT
JANUARY 31, 2024
And what better way to make the time fly than to keep busy. In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes?
Let's personalize your content